Changes in Senior Management, Grants of Orphan Drug Designations, and Updates on Pipeline Development and NDA - Research Report

Changes in Senior Management, Grants of Orphan Drug Designations, and Updates
 on Pipeline Development and NDA - Research Report on Vivus, Omeros, Delcath
                       Systems, Achillion, and Zogenix

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 7, 2013

NEW YORK, October 7, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting VIVUS Inc.
(NASDAQ: VVUS), Omeros Corporation (NASDAQ: OMER), Delcath Systems, Inc.
(NASDAQ: DCTH), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), and Zogenix,
Inc. (NASDAQ: ZGNX). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

VIVUS Inc. Research Report

On September 27, 2013, VIVUS, Inc. (Vivus) announced the resignation of Peter
Y. Tam as the Company's President, effective October 12, 2013. The Company
mentioned that in Mr. Tam's 20 year tenure at VIVUS, he held a broad range of
key management and leadership roles, and was directly responsible for the
efforts to secure the rights, develop and gain approval for four of the
Company's products. "We thank Peter for his invaluable contributions to VIVUS
during two decades of successful service," stated Seth Fischer, CEO of VIVUS.
"Among his many achievements, Peter completed the in-licensing of Qsymia and
STENDRA, and led their subsequent development and approvals. We wish him every
success in his future endeavors." The Full Research Report on VIVUS Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/8ae9_VVUS]

--

Omeros CorporationResearch Report

On September 30, 2013, Omeros Corp. (Omeros) announced that it has received an
orphan drug designation from the U.S. Food & Drug Administrator (FDA) for
OMS824, the Company's phosphodiesterase 10 (PDE10) inhibitor. According to
Omeros, the PDE10 inhibitor is for the treatment of Huntington's disease. "The
manifestations of Huntington's are devastating to both Huntington's patients
and their families, yet there is only one currently approved therapeutic and
it is focused on a single symptom of the disease. OMS824 holds the promise of
expanding treatment across the constellation of debilitating effects of
Huntington's," stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros.
"We look forward to working with the FDA to advance the clinical evaluation of
OMS824 in patients suffering from Huntington's disease and plan to initiate
enrollment in a Phase 2 trial later this year." The Full Research Report on
Omeros Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e3c9_OMER]

--

Delcath Systems, Inc.Research Report

On October 1, 2013, Delcath Systems, Inc. (Delcath Systems) announced that the
US Food & Drug Administration (FDA) has granted the Company orphan drug
designation for melphalan in the treatment of patients with hepatocellular
carcinoma (HCC, or primary liver cancer). According to the Company, the
designation provides the drug developer with a seven-year period of U.S.
marketing exclusivity if the drug is the first of its type approved for the
specified indication or if it demonstrates superior safety, efficacy, or a
major contribution to patient care versus another drug of its type previously
granted the designation for the same indication. The Company informed that the
use of Melphalan with the Delcath Hepatic Delivery System is not currently
approved in the United States for the treatment of patients with HCC. The Full
Research Report on Delcath Systems, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/be47_DCTH]

--

Achillion Pharmaceuticals, Inc.Research Report

On September 27, 2013, Achillion Pharmaceuticals, Inc. (Achillion) announced
updates in the development of compounds in its pipeline of therapies for the
treatment of chronic hepatitis C virus, or HCV. The Company received a
response from the US Food & Drug Administration (FDA) on the clinical hold
related to sovaprevir, Achillion's NS3 protease inhibitor, which indicated
that while Achillion's submission addressed all issues noted in the FDA's June
29, 2013 letter, the FDA concluded that the removal of the clinical hold is
not warranted. "While we are disappointed that we were not able to resolve the
clinical hold at this time despite having addressed all the issues, we believe
the breadth of our portfolio allows us to quickly advance other all oral
combination regimens for the treatment of HCV," stated Milind Deshpande,
President and CEO of Achillion. "With our Phase 2 NS5A inhibitor, ACH-3102, we
are in a position to rapidly initiate combination studies with ACH-2684, our
protease inhibitor, with results expected in 2014. Further, we continue to
advance our uridine-analog nucleotide, ACH-3422, with which we anticipate
initiating clinical trials in the first half of 2014." The Full Research
Report on Achillion Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/04a2_ACHN]

--

Zogenix, Inc.Research Report

On October 1, 2013, Zogenix Inc. (Zogenix) announced that the US Food & Drug
Administration (FDA) has informed the Company that an action letter on the New
Drug Application (NDA) for Zohydro^[^TM^] ER (hydrocodone bitartrate)
extended-release capsules could follow after a further delay of short
duration. The FDA had previously informed the Company that it expected to
issue an action letter over the summer. The Company said that if approved,
Zohydro ER is expected to be the first extended-release formulation
hydrocodone therapy without acetaminophen. The Full Research Report on
Zogenix, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/ef36_ZGNX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.